Compare CNC & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNC | NUWE |
|---|---|---|
| Founded | 1984 | 1999 |
| Country | United States | United States |
| Employees | N/A | 38 |
| Industry | Medical Specialities | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5B | 1.1M |
| IPO Year | 2001 | N/A |
| Metric | CNC | NUWE |
|---|---|---|
| Price | $63.52 | $1.96 |
| Analyst Decision | Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $46.75 | N/A |
| AVG Volume (30 Days) | ★ 2.9M | 106.6K |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $194,777,000,000.00 | N/A |
| Revenue This Year | $8.31 | $11.14 |
| Revenue Next Year | $1.05 | $18.51 |
| P/E Ratio | $20.38 | ★ N/A |
| Revenue Growth | ★ 19.44 | N/A |
| 52 Week Low | $25.08 | $0.08 |
| 52 Week High | $69.36 | $11.22 |
| Indicator | CNC | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 43.95 |
| Support Level | $63.20 | $1.82 |
| Resistance Level | $66.55 | $2.09 |
| Average True Range (ATR) | 2.24 | 0.33 |
| MACD | -0.65 | -0.20 |
| Stochastic Oscillator | 26.36 | 6.71 |
Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.